Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2015 Dec 16;35(6):916–922. doi: 10.1007/s11596-015-1528-9

Antiviral effect of emodin from Rheum palmatum against coxsakievirus B5 and human respiratory syncytial virus in vitro

Zhao Liu 1,2,✉, Nian Ma 2, Yan Zhong 2, Zhan-qiu Yang 2
PMCID: PMC7089517  PMID: 26670446

Abstract

Viral infections are the major causes of morbidity and mortality in elderly people and young children throughout the world. The most common pathogens include coxsackie virus (CV) and respiratory syncytial virus (RSV). However, no antiviral agents with low toxicity and drug resistance are currently available in clinic therapy. The present study aimed to examine the antiviral activities of emodin (an ingredient of Rheum palmatum) against CVB5 and RSV infections, in an attempt to discover new antiviral agents for virus infection. The monomer emodin was extracted and isolated from Rheum palmatum. The antiviral activities of emodin on HEp-2 cells were evaluated, including virus replication inhibition, virucidal and anti-absorption effects, by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tet-razolium bromide (MTT) assay and plaque reduction assay (PRA). The kinetics of virus inhibition by emodin in a period of 14 h was further determined by plaque assay and quantitative real time PCR (qPCR). Cytokine (IFN-γ, TNF-α) mRNA expressions after emodin treatment (7.5, 15, 30 μmol/L) were also assessed by qPCR post-infection. The results showed that emodin had potent inhibitory activities against CVB5 and RSV, with the 50% effective concentration (EC50) ranging from 13.06 to 14.27 μmol/L and selectivity index (SI) being 5.38–6.41 μmol/L. However, emodin couldn’t directly inactivate the viruses or block their absorption to cells. It acted as a biological synthesis inhibitor against CVB4 and RSV in a concentration- and time-dependent manner, especially during the first 0–4 h post-infection. Moreover, emodin could decrease the mRNA expression of IFN-α but enhance TNF-γ expression significantly compared to the viral controls in vitro. Our results provide a molecular basis for development of emodin as a novel and safe antiviral agent for human enterovirus and respiratory virus infection in the clinical therapy.

Key words: emodin, antiviral effect, coxsakievirus B5, respiratory syncytial virus

Footnotes

This project was supported by grants from the National Mega Project on Major Drug Development (No. 2009ZX09301-014-1) and National Natural Science Foundation of China (No. 81371865).

References

  • 1.Pallansch MA. Coxsackievirus B epidemiology and public health concerns. Curr Top Microbiol Immunol. 1997;233:13–30. doi: 10.1007/978-3-642-60687-8_2. [DOI] [PubMed] [Google Scholar]
  • 2.Ramsingh AI. CVB-induced pancreatitis and alterations in gene expression. Curr Top Microbiol Immunol. 2008;323:241–258. doi: 10.1007/978-3-540-75546-3_11. [DOI] [PubMed] [Google Scholar]
  • 3.Chapman NM, Kim KS. Persistent coxsackievirus infection: enterovirus persistence in chronic myocarditis and dilated cardiomyopathy. Curr Top Microbiol Immunol. 2008;323:275–292. doi: 10.1007/978-3-540-75546-3_13. [DOI] [PubMed] [Google Scholar]
  • 4.Antona D, Lévêque N, Chome JJ, et al. Surveillance of enteroviruses in France, 2000-2004. Eur J Clin Microbiol Infect Dis. 2007;26:403–412. doi: 10.1007/s10096-007-0306-4. [DOI] [PubMed] [Google Scholar]
  • 5.Trallero G, Avellon A, Otero A, et al. Enteroviruses in Spain over the decade 1998-2007: virological and epidemiological studies. J Clin Virol. 2010;47:170–176. doi: 10.1016/j.jcv.2009.11.013. [DOI] [PubMed] [Google Scholar]
  • 6.Zhong Q, Yang Z, Liu Y, et al. Antiviral activity of arbidol against Coxsackie virus B5 in vitro and in vivo. Arch Virol. 2009;154(4):601–607. doi: 10.1007/s00705-009-0346-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Han JF, Jiang T, Fan XL, et al. Recombination of human coxsackievirus B5 in hand, foot, and mouth disease patients, China. Emerg Infect Dis. 2012;18:351–353. doi: 10.3201/eid1802.111524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ravi L I, Liang L, Sutejo R, et al. A systems-based approach to analyse the host response in murine lung macrophages challenged with respiratory syncytial virus. Bmc Genomics. 2013;14(3):339–342. doi: 10.1186/1471-2164-14-190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555. doi: 10.1016/S0140-6736(10)60206-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol. 1991;133(11):1135–1151. doi: 10.1093/oxfordjournals.aje.a115826. [DOI] [PubMed] [Google Scholar]
  • 11.MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307(7):397–400. doi: 10.1056/NEJM198208123070702. [DOI] [PubMed] [Google Scholar]
  • 12.Morales F, Calder MA, Inglis JM, et al. A study of respiratory infections in the elderly to assess the role of respiratory syncytial virus. J Infect,7(3):236-247 [DOI] [PubMed]
  • 13.Rotbart HA. Treatment of picornavirus infections. Antiviral Res. 2002;53:83–98. doi: 10.1016/S0166-3542(01)00206-6. [DOI] [PubMed] [Google Scholar]
  • 14.Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med. 2009;29:725–739. doi: 10.1016/j.cll.2009.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mejías A, Chávez-Bueno S, Ríos AM, et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother. 2004;48(5):1811–1822. doi: 10.1128/AAC.48.5.1811-1822.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Krilov LR. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti Infect Ther. 2011;9:27–32. doi: 10.1586/eri.10.140. [DOI] [PubMed] [Google Scholar]
  • 17.Tang T, Yin LW, Yang J, et al. Emodin, an anthraquinone derivative from Rheum officinale Baill, enhances cutaneous wound healing in rats. Eur J Pharmacol. 2007;567:177–185. doi: 10.1016/j.ejphar.2007.02.033. [DOI] [PubMed] [Google Scholar]
  • 18.Reed LJ, Muench HA. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493–497. [Google Scholar]
  • 19.Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007;152:1447–1455. doi: 10.1007/s00705-007-0974-5. [DOI] [PubMed] [Google Scholar]
  • 20.Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005;68(2):66–74. doi: 10.1016/j.antiviral.2005.06.010. [DOI] [PubMed] [Google Scholar]
  • 21.Boulware SL, Bronstein JC, Nordby EC, et al. Identification and characterization of benzothiophene inhibitor of herpes simplex virus type 1 replication which acts at the immediate early stage of infection. Antiviral Res. 2001;51:111–125. doi: 10.1016/S0166-3542(01)00147-4. [DOI] [PubMed] [Google Scholar]
  • 22.Dr Suzanne EM, Rebecca L, Dr Moses KN, et al. Pathogenesis of Coxsackievirus-B5 acquired from intra-renal porcine islet cell xenografts in diabetic mice. Xenotransplantation. 2009;16(2):91–98. doi: 10.1111/j.1399-3089.2009.00522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yuan J, Yu M, Lin QW, et al. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol. 2010;185(7):4004–4010. doi: 10.4049/jimmunol.1001718. [DOI] [PubMed] [Google Scholar]
  • 24.Robert-Tissot C, Ruegger VL, Cattori V, et al. The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation. Vet Immunol Immunopathol. 2011;143(3-4):269–281. doi: 10.1016/j.vetimm.2011.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 26.Chen YC, Shen SC, Lee WR, et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol. 2002;64(12):1713–1724. doi: 10.1016/S0006-2952(02)01386-2. [DOI] [PubMed] [Google Scholar]
  • 27.Kumar A, Dhawan S, Aggarwal BB. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNFinduced NF-kB activation, I?B degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene. 1998;17:913–918. doi: 10.1038/sj.onc.1201998. [DOI] [PubMed] [Google Scholar]
  • 28.Hsiang CY, Ho TY. Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures. Br J Pharmacol. 2008;155:227–235. doi: 10.1038/bjp.2008.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Shuangsuo D, Zhengguo Z, Yunru C, et al. Inhibition of the replication of hepatitis B virus in vitro by emodin. Med Sci Monit. 2006;12:BR302–BR306. [PubMed] [Google Scholar]
  • 30.Schwarz S, Wang K, Yu W, et al. Emodin inhibits current through SARS-associated coronavirus 3a protein. Antiviral Res. 2011;90:64–69. doi: 10.1016/j.antiviral.2011.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Battistutta R, Sarno S D, Moliner E, et al. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem. 2000;275:29618–29622. doi: 10.1074/jbc.M004257200. [DOI] [PubMed] [Google Scholar]
  • 32.Sydiskis RJ, Owen DG, Lohr JL, et al. Inactivation of enveloped viruses by anthraquinones extracted from plants. Antimicrob Agents Chemother. 1991;35:2463–2466. doi: 10.1128/AAC.35.12.2463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kan Q, Li D, Yu Z. Specific expression of human interferon-gamma controls hepatitis B virus replication in vitro in secreting hepatitis B surface antigen hepatocytes. Virol Methods. 2012;180(1-2):84–90. doi: 10.1016/j.jviromet.2011.12.016. [DOI] [PubMed] [Google Scholar]
  • 34.Stubblefield Park SR, Widness M, Levine A D, et al. T cell-, interleukin-12-, and gamma interferon-driven viral clearance in measles virus-infected brain tissue. J Virol. 2011;85(7):3664–3676. doi: 10.1128/JVI.01496-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Henke A, Zell R, Ehrlich G, et al. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis. J Virol. 2001;75:8187–8194. doi: 10.1128/JVI.75.17.8187-8194.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Opavsky MA, Penninger J, Aitken K, et al. Susceptibility to myocarditis is dependent on the response of alpha/beta T lymphocytes to coxsackieviral infection. Circ Res. 1999;85:551–558. doi: 10.1161/01.RES.85.6.551. [DOI] [PubMed] [Google Scholar]
  • 37.Horwitz MS, Krahl T, Fine C, et al. Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon. J Virol. 1999;73:1756–1766. doi: 10.1128/jvi.73.3.1756-1766.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kanda T, Takahashia T, Kudob S, et al. Leptin deficiency enhances myocardial necrosis and lethality in a murine model of viral myocarditis. Life Sci. 2004;75:1435–1447. doi: 10.1016/j.lfs.2004.03.012. [DOI] [PubMed] [Google Scholar]
  • 39.Huber SA, Born W, O’Brien R. Dual functions of murine CD cells in inflammation and autoimmunity in coxsackievirus B3-induced myocarditis: role of Vc1+ and Vc4+ cells. Microbes Infect. 2005;7:537–543. doi: 10.1016/j.micinf.2004.12.011. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Huazhong University of Science and Technology. Medical Sciences are provided here courtesy of Nature Publishing Group

RESOURCES